Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia

Journal of Behavioral Health Services and Research

Volumn 40, Issue 3, 2013, Pages 355-366

  Lin, Jay ^a   Wong, Bruce ^b   Offord, Steve ^c   Mirski, Dario ^c  

^a Novosys Health   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MEDICARE; MEDICINAL CHEMISTRY; MIDDLE AGED; RETROSPECTIVE STUDY; SCHIZOPHRENIA; UNITED STATES; VERY ELDERLY; ARTICLE; CHEMISTRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES;

EID: 84879502816     PISSN: 10943412     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11414-013-9329-z     Document Type: Article

References (22)

1. Horvitz-Lennon M, Donohue JM, Domino ME, et al. Improving quality and diffusing best practices: the case of schizophrenia. Health Affairs 2009;28(3):701-12.
2. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. The Journal of Clinical Psychiatry 2005;66(9):1122-9.
3. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Annals of General Psychiatry 2011;10:10.
4. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. The Journal of Clinical Psychiatry 2002;63(10):892-909.
5. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatric Services 2005;56(3):283-91.
6. Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. The Journal of Clinical Psychiatry 2001;62(7):545-51.
7. Kelin K, Lambert T, Brnabic AJ, et al. Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence 2011;5:213-22.
8. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Current Medical Research and Opinion 2007;23(10):2305-12.
9. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC psychiatry 2010;10:2.
10. Adams C E, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. The British Journal of Psychiatry 2001;179(4):290-299.
11. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35(12):2367-77.
12. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. The New England Journal of Medicine 2011;364(9):842-51.
13. US Department of Health and Human Services. Code of Federal Regulations. Human Subjects Research (45 CFR 46).
14. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophrenia Bulletin 2008;34(5):995-1001.
15. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 2007;58(4):482-8.
16. Bernardo M, San L, Olivares JM, et al. Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. Patient Preference and Adherence 2011;5:601-10.
17. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 2004;30(2):193-217.
18. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 1998;24(1):1-10.
19. Ascher-Svanum H, Peng X, Faries D, et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry 2009;9:46.
20. Akincigil A, Hoover DR, Walkup JT, et al. Hospitalization for psychiatric illness among community-dwelling elderly persons in 1992 and 2002. Psychiatric Services 2008;59(9):1046-8.
21. Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. The Journal of Clinical Psychiatry 2006;67(12):1948-53.
22. Yu AP, Atanasov P, Ben-Hamadi R, et al. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 2009;12(5):708-15.